Estimates Revisions ACADIA Pharmaceuticals Inc.
Stocks
ACAD
US0042251084
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
00:00:00 29/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 29.11 USD | -2.09% |
|
+0.24% | +8.99% |
| 08-25 | Deutsche Bank Adjusts ACADIA Pharmaceuticals PT to $38 From $37, Maintains Buy Rating | MT |
| 08-25 | EU Approves Acadia Pharmaceuticals' Rett Syndrome Drug Daybu | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- ACAD Stock
- Consensus ACADIA Pharmaceuticals Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
